Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: the M. D. Anderson Cancer Center experience
Nora A. Janjan(The University of Texas MD Anderson Cancer Center), John M. Skibber(University of Virginia), Pamela K. Allen(The University of Texas MD Anderson Cancer Center), Vincent Khoo(The University of Texas MD Anderson Cancer Center), James L. Abbruzzese, Gary A. Glober(The University of Texas MD Anderson Cancer Center), Ronelle A. DuBrow(The University of Texas MD Anderson Cancer Center), Tyvin A. Rich(The University of Texas MD Anderson Cancer Center), Robert A. Wolff(The University of Texas MD Anderson Cancer Center), Karen R. Cleary(The University of Texas MD Anderson Cancer Center), Richard Pazdur(United States Food and Drug Administration)
International Journal of Radiation Oncology*Biology*Physics
July 1, 1999
Cited by 468
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k